Center for Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland; Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland.
Center for Molecular Cardiology, University of Zurich, 8952 Schlieren, Switzerland; Department of Internal Medicine, Cantonal Hospital Baden, Baden, Switzerland.
J Mol Cell Cardiol. 2020 Aug;145:84-87. doi: 10.1016/j.yjmcc.2020.06.007. Epub 2020 Jun 18.
We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio.
我们认为，在尝试直接阻断 SARS-CoV-2 进入宿主细胞和药物再利用的同时，还应特别关注寻找治疗 COVID-19 相关肺损伤或心血管并发症/凝血功能障碍患者的新治疗策略。通过抑制血管紧张素转化酶（ACE）和血管紧张素 II（Ang-II）的产生，以及下调血管紧张素受体 1（AT1R）和 ACE2 的上调，apelin 或其受体激动剂在治疗 COVID-19 方面具有很大的潜力。这些药物有可能改善与升高的 Ang-II/Ang(1-7) 比值相关的 COVID-19 中的急性肺损伤和心血管/凝血功能障碍并发症。
